Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences
Theresa M. Carbonaro, Matthew W. Johnson, Ethan Hurwitz, et al.
Psychopharmacology (2017) Vol. 235, Iss. 2, pp. 521-534
Open Access | Times Cited: 116

Showing 1-25 of 116 citing articles:

REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics
Robin Carhart‐Harris, Karl Friston
Pharmacological Reviews (2019) Vol. 71, Iss. 3, pp. 316-344
Open Access | Times Cited: 779
The entropic brain - revisited
Robin Carhart‐Harris
Neuropharmacology (2018) Vol. 142, pp. 167-178
Closed Access | Times Cited: 432
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function
Matthew W. Johnson, Peter S. Hendricks, Frederick S. Barrett, et al.
Pharmacology & Therapeutics (2018) Vol. 197, pp. 83-102
Closed Access | Times Cited: 421
Emotions and brain function are altered up to one month after a single high dose of psilocybin
Frederick S. Barrett, Manoj K. Doss, Nathan D. Sepeda, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 284
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Anne Katrin Schlag, Jacob S. Aday, Iram Salam, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 3, pp. 258-272
Open Access | Times Cited: 222
Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention
Frederick S. Barrett, Samuel R. Krimmel, Roland R. Griffiths, et al.
NeuroImage (2020) Vol. 218, pp. 116980-116980
Open Access | Times Cited: 149
Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects
Friederike Holze, Laura Ley, Felix Müller, et al.
Neuropsychopharmacology (2022) Vol. 47, Iss. 6, pp. 1180-1187
Open Access | Times Cited: 148
Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials
Jacob S. Aday, Boris D. Heifets, Steven D. Pratscher, et al.
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1989-2010
Open Access | Times Cited: 146
Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity
Katrin H. Preller, Patricia Duerler, Joshua B. Burt, et al.
Biological Psychiatry (2020) Vol. 88, Iss. 2, pp. 197-207
Closed Access | Times Cited: 144
Models of psychedelic drug action: modulation of cortical-subcortical circuits
Manoj K. Doss, Maxwell B. Madden, Andrew Gaddis, et al.
Brain (2021) Vol. 145, Iss. 2, pp. 441-456
Open Access | Times Cited: 143
Brain entropy, fractal dimensions and predictability: A review of complexity measures for EEG in healthy and neuropsychiatric populations
Zen Juen Lau, Tam Pham, Shen‐Hsing Annabel Chen, et al.
European Journal of Neuroscience (2022) Vol. 56, Iss. 7, pp. 5047-5069
Open Access | Times Cited: 113
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
Michiel van Elk, David B. Yaden
Neuroscience & Biobehavioral Reviews (2022) Vol. 140, pp. 104793-104793
Open Access | Times Cited: 110
Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants
Laura Ley, Friederike Holze, Denis Arikci, et al.
Neuropsychopharmacology (2023) Vol. 48, Iss. 11, pp. 1659-1667
Open Access | Times Cited: 66
History repeating: guidelines to address common problems in psychedelic science
Michiel van Elk, Eiko I. Fried
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 54
Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis
Yuan Yao, Dan Guo, Tangsheng Lu, et al.
Psychiatry Research (2024) Vol. 335, pp. 115886-115886
Closed Access | Times Cited: 24
Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
Athina-Marina Metaxa, Mike Clarke
BMJ (2024), pp. e078084-e078084
Open Access | Times Cited: 21
Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy
Peter S. Hendricks
International Review of Psychiatry (2018) Vol. 30, Iss. 4, pp. 331-342
Closed Access | Times Cited: 147
Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy
Natalie Gukasyan, Sandeep M. Nayak
Transcultural Psychiatry (2021) Vol. 59, Iss. 5, pp. 652-664
Closed Access | Times Cited: 102
Mystical and Other Alterations in Sense of Self: An Expanded Framework for Studying Nonordinary Experiences
Ann Taves
Perspectives on Psychological Science (2020) Vol. 15, Iss. 3, pp. 669-690
Open Access | Times Cited: 94
Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition
Frederick S. Barrett, Theresa M. Carbonaro, Ethan Hurwitz, et al.
Psychopharmacology (2018) Vol. 235, Iss. 10, pp. 2915-2927
Open Access | Times Cited: 90
Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches
Albert Garcia‐Romeu, Frederick S. Barrett, Theresa M. Carbonaro, et al.
Journal of Psychopharmacology (2021) Vol. 35, Iss. 4, pp. 353-361
Open Access | Times Cited: 72
Dose–response relationships of psilocybin-induced subjective experiences in humans
Tim Hirschfeld, Timo Torsten Schmidt
Journal of Psychopharmacology (2021) Vol. 35, Iss. 4, pp. 384-397
Open Access | Times Cited: 67
Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research
David A. Bender, David J. Hellerstein
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1907-1932
Closed Access | Times Cited: 64
The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT)
Johannes T. Reckweg, Malin V. Uthaug, Attila Szabó, et al.
Journal of Neurochemistry (2022) Vol. 162, Iss. 1, pp. 128-146
Open Access | Times Cited: 59
Structure–Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice
Grant C. Glatfelter, Eline Pottie, John S. Partilla, et al.
ACS Pharmacology & Translational Science (2022) Vol. 5, Iss. 11, pp. 1181-1196
Open Access | Times Cited: 56
Page 1 - Next Page

Scroll to top